Ann: Annual Report to shareholders , page-6

In relation to point #1 I believe this is an upgrade to the current burette, likely based on some feedback from the trials and they want to ensure it is also covered by the patent.

"The innovation sets the correct vent and clamp controls for the AutoStart, AutoFlush, and standard burette functions in a single, simple controller. The invention dramatically simplifies use of the device, which has been one of the main customer concerns."

My understanding is there is a combination of controls they can use for flow and all the other options, so it looks like they are putting these into one controller that does it all. Very smart. They are being very thorough if that is the case so happy about this. Again, just my thoughts on the matter.

In regards to the options, I have to disagree with you there CandN1986. As some have said, no one has endless cash. Remember, the directors supported the company with over $1M in the last rights issue and underwriting it themselves. I imagine they are in a blackout period currently with pending news so can't purchase on market anyway, but what I would prefer to see is once news is released the directors buying up on market.

They again confirmed the US major negotiations. Securing a distributor like J&J or Baxter would be company making overnight. Reason being, this product is used in nearly every hospital over the world, for nearly every patient that requires a drip I believe. It isn't a niche product like a hearing aid or drug with limited market. $3Bn annually ...